# A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

> **NCT01981122** · PHASE2 · COMPLETED · sponsor: **Dendreon** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **BIOLOGICAL:** sipuleucel-T
- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT01981122
- **Lead sponsor:** Dendreon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-06-30
- **Final completion:** 2017-06-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01981122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01981122, "A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01981122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*